AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca 
Welcome,         Profile    Billing    Logout  
 1 Disease   6 Trials   6 Trials   1006 News 


«123456789101112»
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca, enoxaparin sodium / Generic mfg.
    Review, Journal:  Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. (Pubmed Central) -  Dec 8, 2019   
    In the present review, we identified articles via PubMed using the combined keywords andexanet alfa, apixaban, enoxaparin, edoxaban, and rivaroxaban...The use of andexanet alfa requires close monitoring for signs and symptoms of thromboembolic events, ischemic events, and cardiac arrest. Furthermore, anticoagulation should be resumed following the administration of andexanet alfa as soon as medically appropriate.
  • ||||||||||  Journal:  Drugs for atrial fibrillation. (Pubmed Central) -  Nov 18, 2019   
    Furthermore, anticoagulation should be resumed following the administration of andexanet alfa as soon as medically appropriate. No abstract available
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Andexanet alfa-the first 150 days. (Pubmed Central) -  Nov 14, 2019   
    No abstract available No abstract available
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, fondaparinux / Generic mfg.
    Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_5354;    
    Further, it poses an important safety concern as patients requiring emergent cardiac surgery are often hemodynamically unstable and delays in initiation of CPB due to inability to therapeutically heparinize following AnXa administration could adversely affect outcomes. We are currently evaluating whether the effects of AnXa on heparinization translate to increased thrombosis on CPB oxygenator membranes using an in vitro extracorporeal circulation model.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, enoxaparin sodium / Generic mfg.
    Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors (W414AB, Level 4 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_4990;    
    Thrombin generation at 8 h after andexanet bolus did not predict effective hemostasis, intracranial hematoma growth, or thrombotic events. This may be explained by the andexanet dose which was chosen to ensure full reversal of the factor Xa inhibitor in all patients.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, fondaparinux / Generic mfg., enoxaparin sodium / Generic mfg.
    Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_1968;    
    However, AA is incapable of neutralizing the anti-Xa effects of E and F. This may be due to the relatively differential affinities of enoxaparin and fondaparinux AT complex to factor Xa rendering it inhibited in the presence of AA. These studies also demonstrate that the primary surrogate marker anti-Xa activity for measuring the activities of anti-Xa agents is not proportional to the anticoagulant and thrombin generation inhibitory effects of these agents.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Andexanet Response. (Pubmed Central) -  Nov 1, 2019   
    Recruiting --> Completed | Trial completion date: Jan 2020 --> Aug 2019 No abstract available
  • ||||||||||  Review, Journal:  Current status of oral anticoagulant reversal strategies: a review. (Pubmed Central) -  Oct 30, 2019   
    Utilization of direct oral anticoagulants (DOAC) have steadily increased since their approval and are now recommended over warfarin for both stroke prevention in nonvalvular atrial fibrillation and treatment of venous thromboembolism (VTE)...Since then, idarucizumab has been approved for dabigatran reversal and recently, andexanet alfa was granted approval for the reversal of apixaban or rivaroxaban in patients with life-threatening or uncontrolled bleeding events...Data exists describing both prothrombin complex concentrates (PCC) and andexanet alfa for DOAC reversal, however, without head-to-head comparison. Until future studies are available, current literature must be critically evaluated to aid in the clinical decision-making process of how to treat patients with life-threatening DOAC-related bleeding.
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Review, Journal:  Acute treatment of intracerebral hemorrhage (Pubmed Central) -  Oct 24, 2019   
    In recent years, several randomized controlled and observational studies have generated robust evidence regarding ICH treatment; however, there is still no single breakthrough intervention, which significantly improves patient functional outcome. Nevertheless, the sum of various, possibly interacting treatment concepts may potentially improve outcome after ICH.
  • ||||||||||  Review, Journal:  Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update. (Pubmed Central) -  Oct 18, 2019   
    A new generation of anticoagulants, the DOACs, and their reversal agents, are gaining prominence in clinical practice, having demonstrated superior efficacy and safety profiles. They are poised to replace traditional anticoagulants including warfarin.
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Journal:  Management of oral anticoagulation related intracerebral hemorrhage (Pubmed Central) -  Oct 8, 2019   
    In ICH patients using factor-Xa inhibitors, andexanet should be administered as soon as approved in Europe or within clinical studies and if unavailable alternatively high-dose PCC administration...In contrast, VKA resumption in patients with mechanical heart valves should not take place earlier than 1 week after ICH. Generally, safety of OAC resumption appears to be affected by ICH localization along with the presence of cerebral microbleeding, cortical superficial siderosis and cortical/convexity subarachnoid hemorrhage, making it crucial to weigh up the individual patient risk with respect to thromboembolic versus hemorrhagic events.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    MN1-1: Evidence Based Approach to Newer Coagulation Products:  Andexanet (anti-Xa agent reversal), Fibrinogen Concentrate and Freeze Dried Plasma (Hemisfair Ballroom I - Henry B. Gonzalez Convention Center) -  Sep 20, 2019 - Abstract #AABB2019AABB_381;    
    Finally, the potential applications and characteristics of freeze dried plasma (and other similar products in development) will be presented, including their use in the military and their potential in the civilian setting. Examine the evidence to support the use of fibrinogen concentrate during cardiac surgeryDifferentiate between the appropriate use and abuse of Xa inhibitor reversal agentsEvaluate the logistical and clinical rationale for the use for freeze dried plasma versus conventional plasma components.Audience:Transfusion Safety Officer ; Student (MD, MT, SBB) ; CEO ; Medical Director ; Nurse ; Physician ; Research Scientist ; Residents-Fellow Level: Intermediate
  • ||||||||||  Lysteda (tranexamic acid) / Ferring, Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Review, Journal:  Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage. (Pubmed Central) -  Sep 18, 2019   
    Several randomized and large-sized observational studies have considerably expanded the field and the evidence on how to treat acute ICH patients. Yet, the one breakthrough intervention to improve functional outcome is still missing, though various treatment concepts possibly interacting with one another have been evaluated and such treatment bundle may improve patients' outcome.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Review, Journal:  A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet alfa (Andexxa®). (Pubmed Central) -  Sep 16, 2019   
    This accelerated approval was based on change in anti FXa activity from baseline, which indicates a reversal of the anticoagulant effect. Any expanded FDA indication will be contingent on results demonstrating improved hemostasis and efficacy for reversibility of other FXa inhibitors.
  • ||||||||||  Clinical, Review, Journal:  Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists. (Pubmed Central) -  Sep 10, 2019   
    DOACs are associated with lower rates of major and fatal bleeding events compared with warfarin...Idarucizumab and andexanet alfa, which reverse the anticoagulant effects of dabigatran and FXa inhibitors, respectively, are DOAC reversal agents available in the US...However, specific reversal agents are efficacious and safe and should be preferred when available. In this review, we discuss practical issues in the initiation of DOAC therapy, situations where reversal may be needed, coagulation assays, reversal agents, and post-reversal complications in the context of published evidence and guidelines.
  • ||||||||||  enoxaparin sodium / generics
    Efficacy and safety outcomes in FXa-associated bleeding following trauma: an ANNEXA-4 substudy. () -  Sep 10, 2019 - Abstract #EUSEM2019EUSEM_1160;    
    In trauma patients with major bleeding associated with FXa inhibitor use, andexanet alfa resulted in a high rate of excellent or good hemostatic efficacy, with a relatively low occurrence of thrombotic events. These results are comparable to what was observed for ANNEXA-4 patients with spontaneous bleeding events, and suggest that andexanet alfa could be a safe and effective treatment option in the traumatic population.
  • ||||||||||  Clinical, Journal:  Reversal strategies in patients treated with direct oral anticoagulants. (Pubmed Central) -  Sep 6, 2019   
    ...So far, idarucizumab has been the only available antidote that binds specifically to dabigatran and safely and quickly reverses its anticoagulant effects...Recently, the US Food and Drug Administration (FDA) approved andexanet alfa as the first specific antidote for the anti-Xa inhibitors apixaban and rivaroxaban...Because it is so broadly applicable, ciraparantag might be a good future option for the management of most bleeding complications under anticoagulant treatment. The aim of this review is to summarize recent study data and recommendations on nonspecific and specific DOAC reversal strategies and to present the current evidence.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Andexanet Alfa (Andexxa) for the Reversal of Direct Oral Anticoagulants. (Pubmed Central) -  Sep 6, 2019   
    The aim of this review is to summarize recent study data and recommendations on nonspecific and specific DOAC reversal strategies and to present the current evidence. Andexanet alfa (Andexxa) for the reversal of direct oral anticoagulants.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Andexanet Alfa: Preferred Treatment or Therapeutic Option? (Pubmed Central) -  Sep 6, 2019   
    Andexanet alfa (Andexxa) for the reversal of direct oral anticoagulants. No abstract available
  • ||||||||||  Review, Journal:  Reversal agents for non-vitamin K antagonist oral anticoagulants. (Pubmed Central) -  Sep 4, 2019   
    The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit coagulation factor Xa...Three NOAC reversal agents are in various stages of development: idarucizumab, a specific reversal agent for dabigatran; andexanet alfa, which reverses factor Xa inhibitors; and ciraparantag, which is purported to reverse all NOACs...In the absence of licensed reversal agents for the oral factor Xa inhibitors, prothrombin complex concentrates are often used in patients taking these agents who present with life-threatening bleeding. In this Review, we summarize the approved indications for the NOACs, outline how to measure their anticoagulant effects, describe the mechanism of action of the reversal strategies, assess the preclinical and clinical data supporting their use, provide guidance on potential indications for reversal, and offer a management approach for patients treated with NOACs who present with serious bleeding or require urgent surgery.
  • ||||||||||  Clinical, Journal:  How to reverse bleeding in patients on direct oral anticoagulants? (Pubmed Central) -  Aug 30, 2019   
    The direct oral anticoagulants (DOACs), or non-vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, which inhibits thrombin, as well as rivaroxaban, apixaban, edoxaban, and betrixaban, which inhibit coagulation factor Xa, are as-sociated with similar or lower risk of bleeding compared with warfarin...Currently, the only specific reversal agent for dabigatran, idarucizumab, is widely available, while andexanet alfa, which reverses factor Xa inhibitors, was approved in the United States in May 2018...Vitamin K and fresh frozen plasma should not be used to reverse DOACs. This review presents the current evidence regarding bleeding risk on DOACs and the reversal strategies to provide guidance on the management of patients treated with DOACs who experience serious bleeding.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Clinical, Journal:  Spotlight on: reversing anti factor Xa agents and the unmet needs in trauma patients. (Pubmed Central) -  Jul 19, 2019   
    We discuss the impact of this on current practice and review in detail the problems of a neglected and growing clinical area, that of reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.
  • ||||||||||  AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma
    Journal:  Andexanet Alfa for Bleeding with Factor Xa Inhibitors. (Pubmed Central) -  Jul 16, 2019   
    We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved. No abstract available
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, Portola Pharma, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Journal:  Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. (Pubmed Central) -  Jun 26, 2019   
    An antidote of xabans, andexanet-α, was very recently approved by the Food and Drug Administration (FDA)...Other pro-hemostatic agents (FXa, FX (a)-C, FVa) are in pre-clinical stage. The efficacy of these different agents in DOAC reversal and mortality reduction is still controversal in the light of the sparse results of in vitro, ex vivo, pre-clinical and clinical studies.